A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Phase of Trial: Phase III
Latest Information Update: 18 May 2017
At a glance
- Drugs Olokizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CREDO 3
- Sponsors R-Pharm
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Jun 2019 to 1 Jan 2020.
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Sep 2019.